Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of ...

Fintel reports that on November 10, 2025, B. Riley Securities reiterated coverage of Novavax (NasdaqGS:NVAX) with a Buy ...

(Reuters) -Novavax beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...

Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date ...